Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

BACKGROUND: Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expressing programmed death ligand 1 (PD-L1). METHODS: Patients with advanced thyroi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehnert, Janice M., Varga, Andrea, Brose, Marcia S., Aggarwal, Rahul R., Lin, Chia-Chi, Prawira, Amy, de Braud, Filippo, Tamura, Kenji, Doi, Toshihiko, Piha-Paul, Sarina A., Gilbert, Jill, Saraf, Sanatan, Thanigaimani, Pradeep, Cheng, Jonathan D., Keam, Bhumsuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399859/
https://www.ncbi.nlm.nih.gov/pubmed/30832606
http://dx.doi.org/10.1186/s12885-019-5380-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399859/
https://www.ncbi.nlm.nih.gov/pubmed/30832606
http://dx.doi.org/10.1186/s12885-019-5380-3

Ejemplares similares